Practical support for complex head & neck cancer trials

In head and neck cancer trials sponsors are not just working through treatment decisions with one medical oncologist. These studies require multidisciplinary coordination across surgeons, radiation oncologists, medical oncologists, nurses, and broader site teams, while also accounting for imaging complexity, vendors, long-term follow-up, and supportive care needs that can affect whether patients stay on study and contribute valuable efficacy endpoint data. Worldwide helps sponsors plan for those realities early so execution reflects how these studies actually run in practice.

Yes. Head and neck studies often need a broader global strategy to expedite enrollment and access patients. Worldwide’s head and neck cancer experience includes work across 23 countries in North America, Europe, Asia-Pacific, Latin America, and the Middle East, and that matters because treatment access, reimbursement, and standard of care can vary by region in ways that affect feasibility, eligibility, and study positioning from the start.

Worldwide helps sponsors look at standard of care as an operational planning issue, not just a scientific backdrop. In head and neck cancer, differences across countries can affect who is eligible, where enrollment is realistic, what prior therapy patients may have received, and how the study needs to be positioned in each region. Worldwide helps sponsors think through those differences early so country and site decisions are built around real treatment patterns.

Worldwide approaches biomarker prescreening such as HPV16 or p16 as practical drivers of enrollment quality and study pace. In head and neck cancer studies, testing availability can vary by site and region, which can change how quickly patients can be identified and whether a protocol is workable in a given geography. We help sponsors plan with those realities in mind so site selection, screening strategy, and enrollment expectations stay aligned.

Worldwide’s head and neck cancer experience includes studies involving next-generation therapeutic approaches, including gene therapies, targeted therapies, ADCs, and other immunotherapy strategies. The broader value for sponsors is that this experience reflects an indication that has evolved beyond older treatment modalities like radiation and chemotherapy and supports more current thinking around execution.

Worldwide looks at retention as part of study design and operational planning, not only as a problem to solve later. In head and neck oncology, longer follow-up, treatment burden, and supportive-care needs can all affect whether patients remain on study long enough to contribute interpretable data. Worldwide helps sponsors plan with those realities in mind so retention strategy is better connected to patient experience, site support, and data quality.